Protagonist Therapeutics Inc
General ticker "PTGX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.6B
Protagonist Therapeutics Inc follows the US Stock Market performance with the rate: 59.4%.
Estimated limits based on current volatility of 2.3%: low 39.59$, high 41.45$
Factors to consider:
- Current price 28.3% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [15.34$, 31.64$]
- 2024-12-30 to 2025-12-30 estimated range: [14.39$, 30.06$]
Financial Metrics affecting the PTGX estimates:
- Negative: Non-GAAP EPS, $ of -1.49 <= 0.10
- Negative: Operating profit margin, % of -60.95 <= 1.03
- Negative: Operating cash flow per share per price, % of -5.81 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -0.96 < Investing cash flow per share, $ of -0.69
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term PTGX quotes
Long-term PTGX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $27.36MM | $26.58MM | $60.00MM |
| Operating Expenses | $153.20MM | $157.95MM | $153.65MM |
| Operating Income | $-125.84MM | $-131.37MM | $-93.65MM |
| Non-Operating Income | $0.29MM | $3.98MM | $14.70MM |
| R&D Expense | $126.01MM | $126.22MM | $120.16MM |
| Income(Loss) | $-125.55MM | $-127.39MM | $-78.95MM |
| Profit(Loss) | $-125.55MM | $-127.39MM | $-78.95MM |
| Stockholders Equity | $300.02MM | $215.61MM | $336.68MM |
| Inventory | $8.50MM | $0.09MM | $0.00MM |
| Assets | $347.69MM | $247.93MM | $357.95MM |
| Operating Cash Flow | $-107.86MM | $-108.14MM | $-70.24MM |
| Capital expenditure | $1.10MM | $0.80MM | $0.61MM |
| Investing Cash Flow | $-15.86MM | $91.47MM | $-39.26MM |
| Financing Cash Flow | $129.92MM | $18.84MM | $170.48MM |
| Earnings Per Share* | $-2.65 | $-2.52 | $-1.39 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.